To The Editor: We read the article by Witteman et al. ( 1 ) on the effi cacy of EsophyX-2 Transoral Incisionless Fundoplication (TIF) in patients with gastro esophageal refl ux disease (GERD). Th e authors randomized 60 proton pump inhibitor (PPI)-responder patients to TIF ( n =40) vs. continuative PPI-therapy ( n =20). Subjects underwent symptomatic clinical assessment, endoscopy, manometry, and impedance-pH monitoring off -PPI. Th e latter test was carried out in order to objectively prove the presence of pathological acid exposure time (AET) at baseline. Th en, the same tests were repeated at 6 and 12 months aft er surgical and medical therapies. At 6 months follow-up, TIF signifi cantly improved quality of life and refl ux symptoms than the PPI group, whereas AET, total number of refl ux events (NREs), and esophagitis relief were similar in both the groups.
Th is study provides interesting data on the potential use of endotherapy for symptomatic relief in GERD, even if only in the short term, but given the mild eff ect of this technique on AET and NREs, we believe that the interpretation of their fi ndings would have improved if the results of symptom association analysis (SAA) before and aft er TIF were also reported. In fact, even if the presence of a pathological refl ux was an inclusion criteria, it is unclear which and how many symptoms were associated to refl ux. Actually, impedance-pH monitoring allows to measure all kind of refl ux events, thus increasing the diagnostic yield of traditional refl ux monitoring (pH-metry) by using the refl ux-SAA ( 2-4 ). Indeed, several recent studies have shown that GERD patients, in parti cular those with non-erosive refl ux disease, have frequently a normal AET ( 2-6 ), but a positive SAA. Moreover, recent data suggests a role of impedancedetected SAA in predicting the outcome in GERD patients treated with medical or surgical therapy ( 6 ) . Th us, providing this information may be useful to understand whether a particular group of patients should be treated with alternative surgical or endoscopic therapies, and if the benefi t of this technique can be associated to a reduction of refl ux-symptom association rather than to a change in AET or number of refl ux episodes.
So, data concerning the SAA should be investigated and reported also pre-and post-operatively in all studies evaluating the effi cacy of any anti-refl ux procedure in GERD patients. Th is would clarify the role of SAA in determining the indication of surgical or endoscopic therapies and would help to understand its role as a parameter to defi ne an anti-refl ux successful approach.
